NCT04305717
Use of ReDS Technology in Patients With Acute Heart Failure
Recruiting
NAAges 18+InterventionalTreatmentIcahn School of Medicine at Mount SinaiInvestigator-initiated
~240 participants
Updated 2021-02-21 on ClinicalTrials.gov
What's tested:ReDS-guided strategy
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Composite outcome
Measured over 30 days after discharge
Conditions
NCT04305717
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Mount Sinai Hospital
New York, New Yorkstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Donna M Mancini · PRINCIPAL_INVESTIGATOR · Icahn School of Medicine
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Age ≥ 18 years old
Currently hospitalized for a primary diagnosis of HF, including symptoms and signs of fluid overload, regardless of left ventricular ejection fraction (LVEF), and a NT-proBNP concentration of ≥ 400 pg/L or a BNP concentration of ≥ 100 pg/L
Exclusion
Patient characteristics excluded from approved use of ReDS system: height \<155cm or \>190cm, BMI \<22 or \>39
Patients discharged on inotropes, or with a left ventricular assist device or cardiac transplantation
Congenital heart malformations or intra-thoracic mass that would affect right-lung anatomy
End stage renal disease on hemodialysis
Life expectancy \<12 months due to non-cardiac comorbidities
Participating in another randomized study
What this trial measures
- Composite outcome30 days after discharge
A composite of unplanned visit for ADHF that lead to the use of intravenous diuretics, hospitalization for worsening HF, or death from any cause at 30 days after discharge.